Pieter A Van Zwieten
Overview
Explore the profile of Pieter A Van Zwieten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
524
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield M, et al.
Blood Press
. 2009 Dec;
18(6):308-47.
PMID: 20001654
No abstract available.
2.
Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield M, et al.
J Hypertens
. 2009 Oct;
27(11):2121-58.
PMID: 19838131
No abstract available.
3.
de Groot A, Mathy M, Van Zwieten P, Peters S
J Cardiovasc Pharmacol
. 2007 Aug;
50(1):56-60.
PMID: 17666916
Both hypertension and congestive heart failure are characterized by a reduced vasodilatory capacity. In both conditions, the impairment of endothelial function is mainly the result of a reduced nitric oxide...
4.
Van Zwieten P, Mancia G
Semin Cardiothorac Vasc Anesth
. 2006 Sep;
10(3):206-14.
PMID: 16959752
Metabolic syndrome is characterized by a clustering of cardiovascular and metabolic risk factors. This syndrome is now widely recognized as a distinct pathologic entity. It is receiving a great deal...
5.
Nap A, Mathy M, Balt J, Pfaffendorf M, Van Zwieten P
Fundam Clin Pharmacol
. 2004 May;
18(3):309-19.
PMID: 15147282
Sympathetic neurotransmission in tissues with intact sympathetic nerve arborization is extensively dependent on calcium influx via N-type calcium-channels. It was the objective of the present study to assess and compare...
6.
Nap A, Mathy M, Pfaffendorf M, Van Zwieten P
J Cardiovasc Pharmacol
. 2004 Apr;
43(3):432-9.
PMID: 15076228
The present study was designed to investigate the influence of maturation (young versus adult) on the angiotensin II-mediated facilitation of sympathetic nerve traffic (prejunctional AT1-receptor) as well as on the...
7.
Streefkerk J, Balt J, van Montfrans G, van Lieshout J, Pfaffendorf M, Van Zwieten P
J Hypertens
. 2004 Apr;
22(3):551-5.
PMID: 15076161
Objective: It was the objective of this study to investigate whether a facilitatory role of vasopressin (AVP) on sympathetic nerve activity can be demonstrated in humans at the peripheral level....
8.
Streefkerk J, Hoogaars W, Christoffels V, Sand C, Pfaffendorf M, Peters S, et al.
Fundam Clin Pharmacol
. 2004 Jan;
18(1):45-50.
PMID: 14748753
To investigate the involvement of the mitogen-activated protein kinase (MAPK) family of extracellular signal-regulated kinase (ERK) 1 and 2 (MAPKerk1/2) in the vasopressin-mediated vasoconstriction in the rat aorta. Vasopressin-induced vasoconstriction...
9.
Nap A, Belterman C, Mathy M, Balt J, Pfaffendorf M, Van Zwieten P
J Renin Angiotensin Aldosterone Syst
. 2003 Dec;
4(4):220-7.
PMID: 14689369
Congestive heart failure (CHF) is characterised by activation of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system (SNS). Both systems are known to interact and to potentiate each other...
10.
de Groot A, Van Zwieten P, Peters S
J Cardiovasc Pharmacol
. 2003 Dec;
43(1):154-9.
PMID: 14668582
In recent years it has been shown that angiotensin II (Ang II) stimulates formation of reactive oxygen species (ROS), presumably by activation of NAD(P)H oxidase. This ROS formation has been...